capital · May 15, 2026
Isomorphic Labs Announces $2.1 Billion Series B to Advance AI Drug Pipeline
Share the canonical public link.
Isomorphic Labs secured $2.1 billion in Series B funding on May 12, 2026, led by Thrive Capital. The round features Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund as investors. Funds will enhance the IsoDDE AI model for drug discovery and support internal candidate progression. Collaborations with Novartis, Eli Lilly, and Johnson & Johnson integrate IsoDDE into their R&D pipelines with defined milestones. Max Jaderberg serves as president under founder Demis Hassabis at the London headquarters established in 2021.
Failed after 3 attempts. Last error: Service unavailable